Brian V. Slater

Brian V. Slater is a distinguished patent litigator with a primary focus on life sciences and intellectual property disputes, particularly within the pharmaceutical and biotechnology sectors. As a lead trial lawyer, he has extensive experience in high-stakes Hatch-Waxman patent litigations, representing branded pharmaceutical companies against generic drug challengers, as well as complex patent cases involving biologics. His practice also involves counseling emerging and established life sciences companies on protecting, licensing, and monetizing their intellectual property assets. In his tracked appearances, Mr. Slater has consistently represented the plaintiff side, including in the case of IPSEN BIOPHARMACEUTICALS, INC. et al. v. CONJUPRO BIOTHERAPEUTICS, INC. et al.

Mr. Slater currently serves as a Partner and Co-Head of Sterlington PLLC's Intellectual Property practice. Before joining Sterlington, he was associated with Fitzpatrick, Cella, Harper & Scinto. His career highlights include achieving a $1.25 billion settlement for Forward Pharma in a global patent dispute with Biogen, securing an injunction for Merck following a Hatch-Waxman trial concerning its CANCIDAS antifungal drug, and successfully representing Gilead in an AAA arbitration related to its SOVALDI hepatitis C drug. He has been recognized for his work, being selected to Super Lawyers for Intellectual Property Litigation from 2013 to 2026 and earning a Patent Star in the 2025 IP Stars guide for his patent practice in New York and nationally.

While specific individual PTAB/IPR case counts for Mr. Slater are not detailed, Sterlington's IP practice emphasizes significant experience in post-grant patent proceedings before the U.S. Patent and Trademark Office, suggesting his involvement or oversight in such matters given his leadership role. Mr. Slater was admitted to practice in New York in 1991 and earned his Juris Doctor degree from Strathclyde Law School in 1988.